Compare Dishman Pharma with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs BIOCON - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA BIOCON DISHMAN PHARMA/
BIOCON
 
P/E (TTM) x 25.1 31.8 78.8% View Chart
P/BV x 3.3 3.8 88.2% View Chart
Dividend Yield % 0.7 0.3 256.2%  

Financials

 DISHMAN PHARMA   BIOCON
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
BIOCON
Mar-19
DISHMAN PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs374707 52.9%   
Low Rs129554 23.3%   
Sales per share (Unadj.) Rs197.891.9 215.2%  
Earnings per share (Unadj.) Rs21.216.7 126.9%  
Cash flow per share (Unadj.) Rs34.724.2 143.6%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.80.2 501.1%  
Book value per share (Unadj.) Rs179.9101.6 177.0%  
Shares outstanding (eoy) m80.69600.00 13.4%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.36.9 18.5%   
Avg P/E ratio x11.937.7 31.4%  
P/CF ratio (eoy) x7.226.1 27.8%  
Price / Book Value ratio x1.46.2 22.5%  
Dividend payout %9.46.0 157.6%   
Avg Mkt Cap Rs m20,306378,330 5.4%   
No. of employees `0000.86.1 13.5%   
Total wages/salary Rs m5,35511,653 46.0%   
Avg. sales/employee Rs Th19,252.78,994.3 214.1%   
Avg. wages/employee Rs Th6,459.51,900.7 339.9%   
Avg. net profit/employee Rs Th2,064.11,635.3 126.2%   
INCOME DATA
Net Sales Rs m15,96155,144 28.9%  
Other income Rs m2651,444 18.4%   
Total revenues Rs m16,22656,588 28.7%   
Gross profit Rs m4,10315,883 25.8%  
Depreciation Rs m1,0914,478 24.4%   
Interest Rs m944709 133.2%   
Profit before tax Rs m2,33412,140 19.2%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6242,123 29.4%   
Profit after tax Rs m1,71110,026 17.1%  
Gross profit margin %25.728.8 89.3%  
Effective tax rate %26.717.5 152.8%   
Net profit margin %10.718.2 59.0%  
BALANCE SHEET DATA
Current assets Rs m11,01848,228 22.8%   
Current liabilities Rs m9,51730,376 31.3%   
Net working cap to sales %9.432.4 29.0%  
Current ratio x1.21.6 72.9%  
Inventory Days Days11068 161.8%  
Debtors Days Days3586 40.7%  
Net fixed assets Rs m16,30464,130 25.4%   
Share capital Rs m1613,000 5.4%   
"Free" reserves Rs m12,90757,980 22.3%   
Net worth Rs m14,51660,980 23.8%   
Long term debt Rs m4,18915,766 26.6%   
Total assets Rs m29,805121,924 24.4%  
Interest coverage x3.518.1 19.2%   
Debt to equity ratio x0.30.3 111.6%  
Sales to assets ratio x0.50.5 118.4%   
Return on assets %8.98.8 101.2%  
Return on equity %11.816.4 71.7%  
Return on capital %17.516.8 104.6%  
Exports to sales %24.828.1 88.2%   
Imports to sales %3.718.9 19.8%   
Exports (fob) Rs m3,95615,506 25.5%   
Imports (cif) Rs m59610,399 5.7%   
Fx inflow Rs m4,95215,506 31.9%   
Fx outflow Rs m69710,399 6.7%   
Net fx Rs m4,2555,107 83.3%   
CASH FLOW
From Operations Rs m2,78611,546 24.1%  
From Investments Rs m-1,529-7,138 21.4%  
From Financial Activity Rs m-941-2,417 38.9%  
Net Cashflow Rs m3162,103 15.0%  

Share Holding

Indian Promoters % 61.4 40.4 152.0%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 3.7 8.4 44.0%  
FIIs % 12.7 10.7 118.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 19.9 111.1%  
Shareholders   46,261 109,995 42.1%  
Pledged promoter(s) holding % 35.8 0.0 89,400.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   JUBILANT PHARMOVA   DR. DATSONS LABS  FDC  ABBOTT INDIA  PANACEA BIOTECH  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

4 Reasons Why Sensex Surged 848 Points Today(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS